Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of 14C-labeled AL8326 in Healthy Subjects
NCT07132957Phase 1Completed
- Sponsor
- Advenchen Laboratories
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AL8326 in small cell lung cancer (SCLC) and solid tumor, sponsored by Advenchen Laboratories. Primary endpoints: Material balance (Total radioactivity recovery), Metabolite profiling and identification and 2 more. Started Feb 2025; status: completed.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT07132957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132957.